Key Drivers
- Strong cashflow
- Improving margins
- High leverage
AIAI Summary
Takeda is now a cash‑flow–backed, catalyst‑driven recovery story: materially stronger FCF and improving margins mean the stock's upside depends primarily on successful FDA approvals and fast commercial uptake of rusfertide and oveporexton rather than stabilization of legacy revenue. Actionable signals to watch: approval outcomes, early launch metrics (prescriptions, payer coverage), and net leverage/FCF trends—misses on any will likely trigger a swift multiple re‑rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cashflow
- •Improving margins
- •High leverage
Takeda shows stronger near‑term margins and liquidity with very healthy cash generation but remains hampered by low returns on capital, heavy intangible assets and significant leverage/interest burden.
Price Behavior
Key Price Behavior Insights:
- •Below short SMA
- •Near support
- •Lower highs
TAK is trading below its last-month average after a 5–6% pullback from a ~$18.80 peak, holding near $17.70–$17.80 support but needs a sustained break above ~$18.80 to reverse the short-term downtrend.
Rough 5–6% decline from the ~$18.80 peak into mid/late
Sentiment & News
Key News Insights:
- •FDA Priority
- •Investor engagement
- •Pricing scrutiny
Takeda advanced its hematology pipeline with FDA acceptance and Priority Review for rusfertide while engaging investors amid heightened U.S. drug‑pricing scrutiny.
Positive regulatory momentum for rusfertide should boost Takeda's hematology outlook, but commercial risk remains tied to U.S. pricing debates
Similar Companies in Healthcare
Other companies in the same sector with AI ratings